Abbott Laboratories (NYSE:ABT) Updates FY 2025 Earnings Guidance

Abbott Laboratories (NYSE:ABT - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 5.100-5.200 for the period, compared to the consensus estimate of 5.161. The company issued revenue guidance of -. Abbott Laboratories also updated its Q3 2025 guidance to 1.280-1.320 EPS.

Abbott Laboratories Stock Performance

Shares of ABT traded up $3.30 during mid-day trading on Friday, reaching $123.81. The company had a trading volume of 19,570,335 shares, compared to its average volume of 6,275,090. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $141.23. The company has a quick ratio of 1.27, a current ratio of 1.78 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $215.41 billion, a P/E ratio of 16.06, a PEG ratio of 2.50 and a beta of 0.73. The stock has a 50 day moving average of $133.17 and a two-hundred day moving average of $129.38.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%. The firm had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. During the same quarter in the prior year, the business earned $1.14 earnings per share. The company's revenue was up 7.4% compared to the same quarter last year. On average, analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be given a dividend of $0.59 per share. The ex-dividend date is Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.91%. Abbott Laboratories's dividend payout ratio is currently 30.61%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ABT shares. BTIG Research lowered their price target on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a research report on Friday. Leerink Partnrs upgraded Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Morgan Stanley increased their price target on Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research report on Tuesday. Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and increased their price target for the stock from $143.00 to $145.00 in a research report on Friday. Finally, Mizuho increased their target price on Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $144.47.

Insider Activity at Abbott Laboratories

In related news, Director Sally E. Blount sold 2,600 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the sale, the director owned 34,058 shares of the company's stock, valued at approximately $4,415,960.28. This trade represents a 7.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.46% of the company's stock.

Institutional Investors Weigh In On Abbott Laboratories

An institutional investor recently raised its position in Abbott Laboratories stock. Brighton Jones LLC boosted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 51,719 shares of the healthcare product maker's stock after acquiring an additional 4,755 shares during the quarter. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 at the end of the most recent quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.